Tonix
TNXP
Tonix (TNXP) news
Recent news
Tonix Pharmaceuticals Q2 EPS USD -2.44
On August 10, 2026, Tonix Pharmaceuticals (NASDAQ: TNXP) reported Q2 2026 earnings with an EPS of -$2.44, aligning closely with the consensus estimate of -$2.48 . This represents an improvement compared to the Q1 2026 EPS of -$2.93, which missed estimates by $0.39 . The company also reported…
AInvest Wire · Aug 10, 2026Tonix Pharmaceuticals - plans to start Phase 2 TNX-4800 study in Q1 2027
AInvest Wire · Aug 3, 2026Tonix Pharmaceuticals - announces Medicare agreement for Tonmya adding 9 mln lives effective Jan 1, 2027
AInvest Wire · Jul 13, 2026Tonix Pharmaceuticals - primary endpoint is change in MADRS total score at week 6 - SEC filing
AInvest Wire · Jun 29, 2026Tonix Pharmaceuticals - enrolls first patient in Phase 2 Horizon study of TNX-102 SL for MDD - SEC filing
AInvest Wire · Jun 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.